Trial Profile
A Multicenter, Prospective, Real-life Observational Study of Perampanel as Add-on Therapy in Adult and Adolescent Patients With Focal Seizures (A Mirroring Clinical Practice Study of Perampanel in Adults and Adolescents) (The AMPA Study)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Jan 2023
Price :
$35
*
At a glance
- Drugs Perampanel (Primary)
- Indications Seizures; Tonic-clonic epilepsy
- Focus Therapeutic Use
- Acronyms The AMPA Study
- Sponsors Eisai Co Ltd
Most Recent Events
- 06 Dec 2022 Results of post-hoc analysis assessing treatment-emergent adverse events (TEAEs) by seizure type were presented at the 76th Annual Meeting of the American Epilepsy Society.
- 06 Dec 2022 Results of post hoc analysis in a subgroup of patients (greater than equal to 18 years) with excessive daytime sleepiness at baseline (ESS score greater than equal to 11), stratified by the End-of-Study ESS score (less than 11 [normal daytime sleepiness] vs. greater than equal to 11 excessive daytime sleepiness, presented at the 76th Annual Meeting of the American Epilepsy Society.
- 06 Dec 2022 Results assessing the perampanel efficacy and safety data in older adult patients from Studies 412 (NCT02726074; FAME; Korea) and 501 (NCT04257604; AMPA; Italy) who received perampanel as a first or second adjunctive ASM, presented at the 76th Annual Meeting of the American Epilepsy Society.